These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25155930)

  • 41. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.
    López Galera RM; Ribera Pascuet E; Esteban Mur JI; Montoro Ronsano JB; Juárez Giménez JC
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1235-6. PubMed ID: 18712519
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
    Zhu L; Liao S; Child M; Zhang J; Persson A; Sevinsky H; Eley T; Xu X; Krystal M; Farajallah A; McGrath D; Molina JM; Bertz R
    J Antimicrob Chemother; 2012 Feb; 67(2):465-8. PubMed ID: 22121190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
    Kile DA; MaWhinney S; Aquilante CL; Rower JE; Castillo-Mancilla JR; Anderson PL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1227-34. PubMed ID: 22394315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.
    King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL
    J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
    Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
    J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.
    Khanlou H; Farthing C
    J Acquir Immune Defic Syndr; 2005 Aug; 39(4):503. PubMed ID: 16010179
    [No Abstract]   [Full Text] [Related]  

  • 48. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
    Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
    Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
    Colombo S; Buclin T; Cavassini M; Décosterd LA; Telenti A; Biollaz J; Csajka C
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3801-8. PubMed ID: 16940065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
    AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
    Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
    Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
    Guffanti M; De Pascalis CR; Seminari E; Fusetti G; Gianotti N; Bassetti D; Galli A; Castagna A; Lazzarin A
    AIDS; 2003 Dec; 17(18):2669-71. PubMed ID: 14685066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes.
    Wang P; Liu S; Yang J
    Clin Pharmacol Ther; 2024 Aug; 116(2):363-371. PubMed ID: 38429919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole.
    Klomp SD; Veringa A; Alffenaar JC; de Boer MGJ; Span LFR; Guchelaar HJ; Swen JJ
    Clin Transl Sci; 2024 Jul; 17(7):e13887. PubMed ID: 39010708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
    Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
    Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.